Missed the United Nations High-Level Meeting on Antimicrobial Resistance during #UNGA79? Catch up on the key takeaways from our #AMR expert, Gareth Morgan, in his interview with InfectiousDiseaseAdv: bit.ly/3YJ2LdM

Participating in a clinical trial? Check out this list of Dos and Don’ts from the NFXF #FragileXSyndrome #FXS fragilex.org/blog/dos-and-d…

Shionogi leaders, Takuko Sawada and Dr. Pol Vandenbroucke, recently participated in the Global Coalition on Aging’s #SilverEconomyForum. A key theme of the event was the importance of policy solutions and tangible actions to address the disproportionate impact of #AMR on people

#AntimicrobialResistance could potentially cause 1.9M deaths per year by 2050. To help bring attention to the magnitude of #AMR, Shionogi supports World AMR Awareness Week, a global campaign to raise understanding and urgency around AMR. Learn more. #WAAW who.int/campaigns/worl…

We must incentivize the development of critically needed antibiotics and antifungals through the passage of the PASTEUR Act. Take action during World AMR Awareness Week by telling your members of Congress to pass the PASTEUR Act. #AntimicrobialResistance act.pewtrusts.org/uMNGVtD

Hear from Takuko Sawada, Director and Vice Chairperson of the Board, Shionogi & Co., Ltd. and Manica Balasegaram, Executive Director of Global Antibiotic R&D Partnership (GARDP), about how we are working together to increase access to antibiotics, as part of addressing #AMR. #WAAW shionogi.com/content/dam/sh…

This #WAAW, meet our #AMRWarriors. They stand strong in the fight against #AntimicrobialResistance (AMR), one of the top global public health threats. We are committed to ongoing innovation in infectious disease, building on more than 60 years of R&D to create solutions for

We’re looking forward to connecting with the community at the ASHP Midyear Clinical Meeting. Stop by Booth 531 to discover new data on our antibiotic in adults with certain Gram-negative bacterial infections. #ASHP24

Shionogi Inc. welcomes Lynn Connolly, MD, PhD, as Chief Medical Officer of Qpex Biopharma, a Shionogi Group Company. Dr. Connolly will play a pivotal role in guiding clinical development programs and driving innovation for Qpex.

At our recent National Sales Meeting, our sales training and microbiology teams created a Micro Experience Center to help us better understand diagnostics and where our antibiotic may make a difference across seriously ill patient populations.

One of the best parts of coming together is taking time to give back to the community. Our field and corporate-based cross functional teams recently built and decorated skateboards for BGCMia. #greatfutures #corporatecitizenship

明けましておめでとうございます As we welcome the Year of the Snake, we honor the symbolism of wisdom, transformation and renewal, qualities that deeply resonate with Shionogi’s core values. We send our best wishes for health, prosperity and success to the communities we serve.

#NEWS: BARDA's RRPV | Rapid Response Partnership Vehicle has awarded Shionogi funding to address a gap in pre-exposure prophylaxis therapeutics that have the potential to provide protection against severe outcomes of COVID-19. Learn more: bit.ly/4g2E8hF

#NEWS - Two strategic deals with Japan Tobacco’s Pharmaceutical Business: acquiring Akros Pharma & a tender offer for full ownership of Torii Pharmaceutical. These $1B+ transactions strengthen our pipeline and drive our global #innovation. Read more: bit.ly/3YzZ6P1

#BREAKING: The U.S. Food and Drug Administration (#FDA) has accepted a New Drug Application for our investigational oral antiviral for the prevention of COVID-19 following exposure to an infected individual. Learn more: shionogi.com/us/en/news/202…

The #countdown is on to #IDWeek2025! We’ll be sharing 17 scientific presentations from across our anti-infective programs. Learn more about our plans: shionogi.com/us/en/news/202…

#News Gareth Morgan will become President of Qpex, a Shionogi Group Company, and continue his long and impactful journey with our organization. Dr. Mike Dudley is retiring and will remain involved as a strategic advisor.

This year at IDWeek we’re presenting new data from PROVE, an extensive medical chart review study designed to evaluate the safety and effectiveness of our antibiotic in adult patients with serious infections caused by certain Gram-negative pathogens. Read more:

At IDWeek, we will present new data from the SENTRY Antimicrobial Surveillance Program, examining in vitro activity of our antibiotic against high-priority Gram-negative clinical isolates. Join for presentation 627 on 10/22 at 1:57pm ET. Read more: shionogi.com/us/en/news/202…

#News: Our parent company completed the acquisition of Japan Tobacco Inc.’s (JT) pharmaceutical business. As part of this transaction, the NJ-based Akros Pharma Inc., formerly a subsidiary of JT, has become a subsidiary of Shionogi Inc. shionogi.com/us/en/news/202…